Thursday - March 5, 2026
Sanofi and Regeneron's Dupixent Recommended for EU Approval to Treat Chronic Spontaneous Urticaria in Young Children With Ongoing Symptoms Despite Treatment
February 28, 2026
PARIS, France, Feb. 28 -- Sanofi, a life sciences company, issued the following news release:

* * *

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

* If appr . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products